Australian venture capital firm OneVentures is preparing to launch a new healthcare-focused fund later this year. This follows a $250 million raise for its Growth Fund VII, which began in August.
Potential investors may scrutinize the performance of OneVentures' previous fund, particularly given anticipated losses on its $170 million Fund III (2016). Key investments like Vaxxas ($1.3 billion valuation) and Phocas ($450 million valuation) will likely be under examination for their exit strategies and overall profitability.
Michelle Deaker’s OneVentures, widely regarded as one of Australia’s shrewdest venture capital investors, is gearing up to raise a new healthcare-focused fund later this year. However, the effort won’t be without prospective investors questioning the exit status at its biggest moneymakers, including the $1.3 billion vaccine patch start-up Vaxxas and the $450 million analytics software player Phocas.
The venture capital investor has told its backers it expects to launch a dedicated healthcare fund in the December quarter, once it has wrapped up the $250 million raising it kicked off for its Growth Fund VII in August.
Loading...
If you often open multiple tabs and struggle to keep track of them, Tabs Reminder is the solution you need. Tabs Reminder lets you set reminders for tabs so you can close them and get notified about them later. Never lose track of important tabs again with Tabs Reminder!
Try our Chrome extension today!
Share this article with your
friends and colleagues.
Earn points from views and
referrals who sign up.
Learn more